Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates.

"Transparency declaration: A.T., J.H. and P.D.A have no conflicts of interest to declare. M.V. has acted as a consultant for GSK outside the focus of this work, has received speakers fees from Astellas, IPSEN, Mylan and is on an Advisory board for IBSA PHARMA. C. H. has received speakers fees from Astellas, Allergan and Medtronic and is on Advisory boards for Astellas, Teleflex Medical, GSK, Viatris and Convatec. C.H. is also a member of the European Association of urology Female LUTS committee (chair) and the ICS Urodynamic, Mesh complications and Male LUTS committee."

"Funding The AnTIC trial was funded by NIHR HTA (no. 11/72/01). Direct funding for this project has included support for M.V. through European Association of Urology and Association Française D’Urologie Funding; EAU (Ref. ESUP/Scholarship S-02-2018) and AFU (Ref. Bourse AFU 2017). A.T. was a self-funded PhD thesis aided by a Newcastle University Overseas Research Scholarship. C.H. reiceves funding outside the scope of this work from UK National Institute of Health Research and The Urology Foundation."